Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences (USNA) plunged 30% this week after the nutrition and supplements company reported second-quarter results that fell far short of Wall Street estimates. The company posted adjusted earnings of $0.07 per share on sales of $223 million, both significantly below analyst expectations.

The selloff intensified after Usana disclosed a $29 million goodwill impairment charge tied to its Hiya business unit. Management slashed full-year guidance, now projecting an $11 million loss compared to prior guidance of $20 million to $27 million in profit. The company also lowered its full-year revenue outlook to $910 million from a previous range of $925 million to $1 billion.

The guidance reversal marks a dramatic shift for the Utah-based direct-seller, which now faces profitability headwinds alongside weakening sales momentum. The Hiya impairment suggests issues integrating or realizing value from the children's vitamin brand.